Florence, South Carolina 2021-06-08 12:06:46 –
Raleigh, NC (WNCN) — For the first time in almost 20 years, the FDA has approved a new drug to treat Alzheimer’s disease and it was manufactured in this triangle.
This is the first approved treatment designed to stop the progression of the disease itself, rather than simply treating the condition, giving hope to many patients and caregivers, but doctors say this is. It warns that it is not a cure, and its effect is not yet clear.
When Jay Reinstein noticed some memory issues, he initially blamed information overload. At the time, he was 57 years old and worked as an assistant to City Manager in Fayetteville. After that, the problem progressed.
“There were some really simple questions I should have known but couldn’t remember,” he recalled.
The doctor diagnosed juvenile Alzheimer’s disease.
“As I say, it was really an intestinal punch,” Reinstein said.
A few years later, he was excited to learn that the FDA approved a drug designed to slow the progression of the disease. “To be honest, I felt chills because we had been waiting for something so long,” he said.
Biogen provides antibody treatment called aducanumab or aduhelm. The drug is manufactured in the triangle.
Dr. Maha Rada Krishnan, Biogen’s Chief Medical Officer, said: “
According to doctors, this monthly injectable treatment reduces plaque in the brain associated with Alzheimer’s disease, but it is not clear how effective it is in reducing the symptoms of cognitive decline.
“More importantly, how they think, how they can recognize people, and whether they can remember things better.” Director of the Duke Center for the Study of Aging and Human Development. Dr. Heather Whitson said: “Can they maintain their ability to take care of themselves longer? These are some of the questions that have not yet been fully answered.”
She said, “What we don’t want to do is take people to the wrong path of hope. It’s important to understand that this is not a cure and we still don’t know what the benefits are. But we know it will get rid of plaque in the brain. If you start long enough and early enough, there may be some benefit. “
Reinstein knows that the drug may not work for him, but he spoke in support of the FDA Advisory Board.
“The message we sent was.’Why?’ It helps little by little, and this is a step for the baby,” he said.
“I think it’s the beginning of a new era,” Whitson added. “I think more of this will come out.”
For now, Reinstein wants you to try this treatment. “I’m thinking I have a chance to be on that list.”
The FDA has approved the drug, but says Biogen needs to continue research to see if it works.
Biogen states that the drug may be in the hands of healthcare providers within two weeks, but patients must qualify through diagnostic tests.
It is not yet clear how insurance companies will cover this drug.
Alzheimer’s patients excited about newly-approved treatment, though doctors advise caution Source link Alzheimer’s patients excited about newly-approved treatment, though doctors advise caution